CardioTech nears human trials for synthetic CABG (coronary artery bypass surgery):
This article was originally published in Clinica
CardioTech International says that it is preparing to enter clinical trials outside the US to assess its synthetic coronary artery bypass graft (CABG), after recently concluding bench and pre-clinical animal trials of the device. The polyurethane-based product, called CardioPass, could address a market that is expected to exceed $1.5bn annually, says the Woburn, Massachusetts firm.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Commissioner Hahn’s tweet announcing a return to inspections, while not a new policy, may be signal that FDA understands sponsor concerns with the agency’s limited ability to conduct onsite inspections. Effort may be aimed at reassuring industry even as CRLs related to manufacturing increase.
Rushed final rule seeking to impose draconian cuts on drug reimbursement rates in the Medicare Part B program is certain to face legal and political obstacles. But the data included on international price benchmarks will still have an impact.